JP7091357B2 - 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント - Google Patents

哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント Download PDF

Info

Publication number
JP7091357B2
JP7091357B2 JP2019551508A JP2019551508A JP7091357B2 JP 7091357 B2 JP7091357 B2 JP 7091357B2 JP 2019551508 A JP2019551508 A JP 2019551508A JP 2019551508 A JP2019551508 A JP 2019551508A JP 7091357 B2 JP7091357 B2 JP 7091357B2
Authority
JP
Japan
Prior art keywords
cells
seq
drug
system capable
chimeric antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019551508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500563A (ja
JP2020500563A5 (enExample
Inventor
ジェンセン，マイケル，シー．
ウーイ，トレイシー
ウェイ，ジア
Original Assignee
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） filed Critical シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート）
Publication of JP2020500563A publication Critical patent/JP2020500563A/ja
Publication of JP2020500563A5 publication Critical patent/JP2020500563A5/ja
Priority to JP2022096360A priority Critical patent/JP7392043B2/ja
Application granted granted Critical
Publication of JP7091357B2 publication Critical patent/JP7091357B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
JP2019551508A 2016-12-12 2017-12-11 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント Active JP7091357B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096360A JP7392043B2 (ja) 2016-12-12 2022-06-15 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433183P 2016-12-12 2016-12-12
US62/433,183 2016-12-12
PCT/US2017/065597 WO2018111763A1 (en) 2016-12-12 2017-12-11 Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096360A Division JP7392043B2 (ja) 2016-12-12 2022-06-15 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント

Publications (3)

Publication Number Publication Date
JP2020500563A JP2020500563A (ja) 2020-01-16
JP2020500563A5 JP2020500563A5 (enExample) 2021-07-29
JP7091357B2 true JP7091357B2 (ja) 2022-06-27

Family

ID=62559136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019551508A Active JP7091357B2 (ja) 2016-12-12 2017-12-11 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント
JP2022096360A Active JP7392043B2 (ja) 2016-12-12 2022-06-15 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096360A Active JP7392043B2 (ja) 2016-12-12 2022-06-15 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント

Country Status (8)

Country Link
US (2) US11408005B2 (enExample)
EP (1) EP3551197B1 (enExample)
JP (2) JP7091357B2 (enExample)
CN (1) CN110291200B (enExample)
AU (1) AU2017375630B2 (enExample)
CA (1) CA3045665A1 (enExample)
MX (1) MX2019006631A (enExample)
WO (1) WO2018111763A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP2017515464A (ja) 2014-04-10 2017-06-15 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 細胞免疫療法のための方法および組成物
AU2016306209B2 (en) 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
EP3551197B1 (en) 2016-12-12 2023-11-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
AU2019209432B2 (en) 2018-01-22 2026-01-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
AU2019218729B2 (en) * 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
MX2020013977A (es) 2018-06-22 2021-06-15 Kite Pharma Inc Proteínas quiméricas transmembrana y usos de las mismas.
SG11202100205UA (en) * 2018-07-10 2021-02-25 Precigen Inc Ror-1 specific chimeric antigen receptors and uses thereof
JP7399157B2 (ja) * 2018-08-28 2023-12-15 北京永泰瑞科生物科技有限公司 改良された治療用ｔ細胞
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
US12241061B2 (en) 2019-02-04 2025-03-04 National University Corporation Ehime University CAR library and scFv manufacturing method
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
EP3937975A4 (en) * 2019-03-13 2023-06-21 Seattle Children's Hospital (DBA Seattle Children's Research Institute) FLUORESCEIN SODIUM AS AN INVERSION AGENT FOR ANTI-FLUORESCEIN CAR-T CELLS AND FLUORESCEIN-PHOSPHOLIPID ETHERS OR PHOSPHOLIPID-PHOSPHOLIPID ETHERS
WO2020219425A1 (en) * 2019-04-25 2020-10-29 Seattle Children's Hospital (dba Seattle Children's Research Institute) Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
WO2020257823A2 (en) * 2019-06-21 2020-12-24 Kite Pharma, Inc. TGF-β RECEPTORS AND METHODS OF USE
CA3160614A1 (en) * 2019-12-12 2021-06-17 Marcela GUZMAN AYALA Method and compositions for regulated armoring of cells
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US20230242936A1 (en) * 2020-05-14 2023-08-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Dual promoter systems
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
KR20230021022A (ko) * 2020-06-08 2023-02-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-cd171 키메라 항원 수용체
CN111848819A (zh) * 2020-07-31 2020-10-30 广东昭泰体内生物医药科技有限公司 一种靶向msln的嵌合抗原受体及其应用
WO2022076685A1 (en) * 2020-10-09 2022-04-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions comprising pd1 chimeric polypeptides
WO2022125387A1 (en) * 2020-12-08 2022-06-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
WO2022174035A2 (en) * 2021-02-12 2022-08-18 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Activity-inducible fusion proteins having a heat shock protein 90 binding domain
CA3221378A1 (en) * 2021-04-15 2022-10-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for producing and using cell-based immunotherapies to target tumors
WO2022241289A2 (en) * 2021-05-14 2022-11-17 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Activity-inducible fusion proteins having a transcription factor and a heat shock protein 90 binding domain
CN116514982B (zh) * 2021-12-29 2023-12-19 华道(上海)生物医药有限公司 一种抗IL13Ra2的纳米抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535906A (ja) 2003-10-24 2007-12-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 直交遺伝子スイッチ
WO2015157432A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug related transgene expression

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
US20020111474A1 (en) 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
WO1994000143A1 (en) 1992-06-01 1994-01-06 New England Medical Center Hospitals, Inc. Blocking intercellular interactions with cd43 chimeric molecules
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
GB0015119D0 (en) 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
CA2413156C (en) 2000-07-03 2009-08-18 Gala Design, Inc. Expression vectors
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (en) 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
WO2002097050A2 (en) * 2001-05-31 2002-12-05 Novartis Ag Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US20030228606A1 (en) 2002-04-11 2003-12-11 Amgen Inc., A Corporation Of The State Of Delaware Her-2 receptor tyrosine kinase molecules and uses thereof
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20060160090A1 (en) 2003-04-11 2006-07-20 Macina Robert A Composition splice variants and methods relating to cancer specific genes and proteins
WO2005017102A2 (en) 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2005012527A1 (en) 2003-07-21 2005-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7935510B2 (en) * 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
AU2006327175A1 (en) 2005-12-21 2007-06-28 Medimmune, Llc Epha2 bite molecules and uses thereof
US8148129B2 (en) * 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
WO2008012237A1 (en) 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
US7709253B2 (en) 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
DK2279253T3 (en) 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
HRP20211788T1 (hr) 2008-08-26 2022-02-18 City Of Hope Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
KR102025502B1 (ko) 2008-09-26 2019-09-25 토카겐 인크. 유전자 요법 벡터와 시토신 디아미나아제
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
EP2438443A4 (en) 2009-06-02 2012-07-25 Targeted Molecular Diagnostics Llc METHOD FOR DETECTING AND QUANTIFYING THE P95 COMPONENT OF HER2 / NEU (ERBB2)
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
HUE044461T2 (hu) 2009-11-03 2019-10-28 Hope City Csonkolt epidermális növekedési faktor receptor (EGFRT) transzdukált T-sejt szelekcióhoz
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EA201391059A1 (ru) 2011-01-18 2014-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции для лечения рака и способы их применения
SG10201602253SA (en) 2011-03-23 2016-05-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
WO2012140130A1 (en) 2011-04-13 2012-10-18 Immunicum Ab Method for proliferation of antigen-specific t cells
CN110229235A (zh) 2011-06-22 2019-09-13 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
ITRM20120058A1 (it) 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
JP2015509717A (ja) 2012-02-22 2015-04-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗腫瘍活性およびｃａｒ存続性を強化するためのｉｃｏｓベースのｃａｒの使用
EA201990959A1 (ru) 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013177533A1 (en) 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
AU2013267350A1 (en) 2012-05-30 2015-01-29 Baylor College Of Medicine Supercoiled MiniVectors as a tool for DNA repair, alteration and replacement
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
US9792559B2 (en) 2012-06-01 2017-10-17 Nec Corporation Switching system, line card, switch card, FDB learning method, FDB learning arbitration method and program
BR112015002816A8 (pt) 2012-08-20 2023-04-18 Hutchinson Fred Cancer Res Método e composições para imunoterapia celular
WO2014039044A1 (en) 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
EP3456818B1 (en) 2013-03-07 2020-05-20 Baylor College of Medicine Targeting cd138 in cancer
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
SG11201603484PA (en) 2013-11-21 2016-05-30 Ucl Business Plc Cell
CA2934436A1 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
EP3626748A1 (en) 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
AU2016306209B2 (en) 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
ES2879700T3 (es) 2016-02-05 2021-11-22 Hope City Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central
EP3551197B1 (en) 2016-12-12 2023-11-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535906A (ja) 2003-10-24 2007-12-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 直交遺伝子スイッチ
WO2015157432A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug related transgene expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chen, L.-F. et al.，NF-kappaB RelA phosphorylation regulates RelA acetylation，Mol. Cell. Biol.，2005年，Vol. 25，pp. 7966-7975
Roscilli, G. et al.，Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor，Mol. Ther.，2002年，Vol. 6，pp. 653-663
Yang, X.-D. et al.，Functional interplay between acetylation and methylation of the RelA subunit of NF-kappaB，Mol. Cell. Biol.，2010年，Vol. 30，pp. 2170-2180

Also Published As

Publication number Publication date
JP2022130485A (ja) 2022-09-06
AU2017375630A1 (en) 2019-06-13
CN110291200B (zh) 2024-05-14
US20200181624A1 (en) 2020-06-11
CN110291200A (zh) 2019-09-27
MX2019006631A (es) 2019-11-12
US20220411805A1 (en) 2022-12-29
WO2018111763A9 (en) 2018-07-19
AU2017375630B2 (en) 2023-12-21
EP3551197B1 (en) 2023-11-22
EP3551197A1 (en) 2019-10-16
US11408005B2 (en) 2022-08-09
EP3551197A4 (en) 2020-10-28
JP2020500563A (ja) 2020-01-16
WO2018111763A1 (en) 2018-06-21
CA3045665A1 (en) 2018-06-21
JP7392043B2 (ja) 2023-12-05

Similar Documents

Publication Publication Date Title
JP7091357B2 (ja) 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント
JP7093385B2 (ja) 薬物制御による導入遺伝子の発現
CN117721084A (zh) 靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法
CN110997920A (zh) 新型细胞标签的表达
KR20210013691A (ko) 수정된 링커 도메인을 갖는 키메라 항원 수용체 및 그 용도
CN113412276A (zh) 二聚化剂调节的免疫受体复合物
CN111378046B (zh) 一种免疫效应细胞转换受体
TW202144569A (zh) 用於調節免疫細胞中精胺酸含量之方法及組合物
HK40061934A (en) Drug related transgene expression
HK1233274B (en) Drug related transgene expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220615

R150 Certificate of patent or registration of utility model

Ref document number: 7091357

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250